- Home
- REBN vs EVAX Comparison
REBN vs EVAX Comparison
Compare REBN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | EVAX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 42.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REBN | EVAX |
|---|---|---|
| Price | $1.47 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 59.2K | ★ 109.7K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,663,303.00 | ★ $7,650,000.00 |
| Revenue This Year | $335.98 | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.09 | ★ 132.17 |
| 52 Week Low | $1.20 | $1.20 |
| 52 Week High | $8.30 | $12.15 |
Technical Indicators
Market Signals| Indicator | REBN | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 42.56 |
| Support Level | $1.36 | $4.60 |
| Resistance Level | $1.56 | $6.70 |
| Average True Range (ATR) | 0.13 | 0.53 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 19.17 | 13.79 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.